Immuneering CorpIMRX
What Immuneering Corp does.
We are a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive . We are developing and seeking to commercialize an entirely new category of anti-cancer medicines, Deep Cyclic Inhibitors, which we believe have the potential to be more effective and better tolerated targeted therapies.
Deep Cyclic Inhibition® ("DCI") is a novel mechanism that aims to deprive tumor cells of the sustained proliferative signaling required for rapid growth, while sparing healthy cells through a cadenced, normalized level of signaling. Our Deep Cyclic Inhibitors inhibit clinically-validated core signaling pathways, such as the mitogen-activated protein kinase ("MAPK") pathway. Our novel approach is designed to improve durability and tolerability, and differentiates us from chronically targeted precision therapies, which are generally limited by toxicity, resistance and/or application to specific mutations only .
Our lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of mitogen-activated protein kinase kinase (" MEK"), designed to improve durability and tolerability across many cancer indications, including MAPK pathway-driven tumors such as pancreatic cancer. We are currently in the process of initiating a Phase 3 clinical trial of atebimetinib, which we call the MAPKeeper 301 trial, to evaluate atebimetinib in combination with modified gemcitabine/nab-paclitaxel ("mGnP") in first-line pancreatic cancer patients. We expect to dose the first patient in the MAPKeeper 301 trial in mid-2026.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $2.3M | $2.1M | $316,952 | $0 | — | — |
| Net income | -$17.0M | -$33.5M | -$50.5M | -$53.5M | -$61.0M | -$56.0M |
| Free cash flow | -$14.7M | -$30.9M | -$44.8M | -$49.3M | -$55.1M | -$45.5M |
More on IMRX.
- Immuneering Corp summary
- Immuneering Corp financial statements
- Immuneering Corp key metrics
- Immuneering Corp health scores and style box
- Immuneering Corp earnings
- Immuneering Corp dividends
- Immuneering Corp valuation
- Immuneering Corp ownership and insiders
- Immuneering Corp peers
Figures from Immuneering Corp's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.